Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
03/2003
03/13/2003WO2003020253A2 Pharmaceutical compositions for the treatment of asthma
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002072033A3 Chronotherapeutic dosage forms containing glucocorticosteroid
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002052270A3 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/13/2003WO2002050286A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002045703A3 Mixtures or organic compounds for the treatmentof airway diseases
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036553A3 Substituted alkanoic acids
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002022113A3 Retinoic acid receptor antagonists as promoters of angiogenesis
03/13/2003WO2001060413A3 Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050337 Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5- dimethyl-5H-furan-2-one
03/13/2003US20030050329 Synergistic combination comprising roflumilast and a PDE-3 inhibitor
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050290 Combination of formoterol and mometasone furoate for asthma
03/13/2003US20030050278 Agent and food for inhibiting IgE antibody
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050261 Immunostimulatory nucleic acid molecules
03/13/2003US20030050249 Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
03/13/2003US20030050247 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030049706 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of bacterial infections
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049617 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
03/13/2003US20030049322 Aqueous-based pharmaceutical composition
03/13/2003US20030049321 Process for producing fine medicinal substances
03/13/2003US20030049318 Sustained release formulations of guaifenesin and additional drug ingredients
03/13/2003US20030049271 Diagnosis, therapy of bacteria infections
03/13/2003US20030049266 Induce immunology response usin gpolynucleotide
03/13/2003US20030049261 Administering chitinase inhibitor
03/13/2003US20030049255 Interleukin-1 receptors in the treatment of diseases
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003CA2459413A1 Methods for sterilizing preparations containing albumin
03/13/2003CA2457926A1 Pharmaceutical compositions for the treatment of asthma
03/13/2003CA2457861A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2456904A1 Aerosolized decongestants for the treatment of sinusitis
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1291345A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/12/2003EP1291015A1 Dosage forms having prolonged active ingredient release
03/12/2003EP1291013A2 Storage-stable pharmaceutical compositions
03/12/2003EP1290193A2 Protein phosphatases
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1290167A1 Human kcnq5 potassium channel, methods and compositions thereof
03/12/2003EP1290021A2 Polynucleotide sequence encoding a putative cell adhesion molecule
03/12/2003EP1289997A1 Macrolides
03/12/2003EP1289993A1 Caspase inhibitors and uses thereof
03/12/2003EP1289992A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
03/12/2003EP1289990A1 Tetracyclic diketopierazine compounds as pdev inhibitors
03/12/2003EP1289989A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
03/12/2003EP1289985A2 Beta-carboline derivatives useful as inhibitors of phosphodiesterase
03/12/2003EP1289980A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
03/12/2003EP1289972A1 Serine protease inhibitors
03/12/2003EP1289965A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
03/12/2003EP1289964A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
03/12/2003EP1289961A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
03/12/2003EP1289958A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a)
03/12/2003EP1289957A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
03/12/2003EP1289956A1 Chemical compounds
03/12/2003EP1289955A1 Piperidines for use as orexin receptor antagonists
03/12/2003EP1289950A1 Serine protease inhibitors
03/12/2003EP1289945A1 Aniline disulfide derivatives for treating allergic diseases
03/12/2003EP1289944A2 Thioketals and thioethers for inhibiting the expression of vcam-1
03/12/2003EP1289566A1 Ubiquitin promoter in vectors for gene therapy in respiratory tract
03/12/2003EP1289560A1 Novel solid dispersion compositions
03/12/2003EP1289543A2 Formulations and methods for treating hypercoagulable states
03/12/2003EP1289539A1 Pharmaceutical anti-inflammatory aerosol formulation
03/12/2003EP1289525A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/12/2003EP1289506A1 Novel composition
03/12/2003EP1289505A1 Novel process
03/12/2003EP1289501A1 Novel aqueous anti-inflammatory pharmaceutical formulation
03/12/2003EP1289500A1 Novel pharmaceutical formulation suitable for nebulisation
03/12/2003EP1289499A1 Pharmaceutical anti-inflammatory aerosol formulation
03/12/2003EP1289498A1 Novel pharmaceutical formulation suitable for nebulisation
03/12/2003EP1289497A1 Novel aqueous anti-inflammatory pharmaceutical formulation
03/12/2003EP1137430B1 Therapeutic agent for the suppression of snoring noises
03/12/2003EP1083891B1 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
03/12/2003EP1075477B1 Novel Benzonaphthyridine-N-oxides
03/12/2003EP0787016B1 Secretory leukocyte protease inhibitor (slpi) as an inhibitor of tryptase
03/12/2003EP0763039B1 42-rapamycin hydroxyester, process for its preparation and pharmaceutical compositions containing it
03/12/2003EP0758243B1 BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa
03/12/2003EP0672031B1 Catechol diethers as selective pde iv inhibitors
03/12/2003CN1402792A Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
03/12/2003CN1402780A 感染性克隆 Infectious clone
1 ... 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 ... 878